ICH Q12 in the Revised EU Variations Framework: Making PACMPs and Established Conditions Work

Since 15 January 2026, every new variation submitted in the EU has been assessed against the revised Variations Guidelines that accompany Regulation (EU) 2024/1701. The new framework gives marketing authorisation holders more room to plan post-approval changes in advance, and the ICH Q12 toolbox, particularly post-approval change management protocols, is the way to use that room.

What changed in the framework

Regulation (EU) 2024/1701 amended the long-standing Variations Regulation (EC) No 1234/2008 and has applied since 1 January 2025. The detailed classification rules followed in the Commission’s Variations Guidelines (C/2025/5045), which replaced the 2013 guidelines from 15 January 2026. Key features include:

  • Risk-based reclassification: a number of changes have moved down a category, from Type II to Type IB or from Type IB to Type IA, provided every listed condition is met.
  • Clearer grouping and worksharing, including structured “super-grouping” across several authorisations.
  • Device-related categories for integral drug-device combinations, aligned with the Medical Device Regulation.
  • Explicit support for forward planning, building on the principles of ICH Q12.

ICH Q12 in brief

ICH Q12 provides a common language for managing chemistry, manufacturing and controls (CMC) changes across a product’s life. Its main tools are:

  • Established conditions (ECs): the elements of the dossier considered necessary to assure product quality, so that changes to them need regulatory action while other details can be managed within the pharmaceutical quality system.
  • Post-approval change management protocols (PACMPs): an agreed plan describing a future change, the studies that will support it and the acceptance criteria. Once the protocol is approved, implementing the change usually follows a lower reporting category.
  • The product lifecycle management (PLCM) document: a summary of ECs, reporting categories and committed protocols.

Where PACMPs pay off

PACMPs are most valuable for changes that are predictable and likely to be repeated, such as:

  • adding a manufacturing or testing site after a technology transfer
  • scaling up batch size as demand grows
  • replacing an analytical method with a more modern procedure
  • introducing an alternative supplier of a starting material or packaging component.

The pay-off is predictability. Agreeing the scientific approach first separates the debate about acceptance criteria from the time-critical moment of implementation. For a supply-sensitive product, that can be the difference between a smooth site transfer and a stock-out.

Practical pitfalls

  • Vague protocols: a PACMP that does not specify the studies, data and acceptance criteria tends to attract questions and loses most of its value.
  • Weak PQS evidence: regulators will only accept lower reporting categories if the pharmaceutical quality system can be trusted to manage change. Inspection history and change-control maturity matter.
  • Transition errors: for Type IA changes, the reference point under the new guidelines is the implementation date in the quality system, not the submission date, which affects annual-update cycles.
  • National alignment: for products authorised through national, mutual recognition or decentralised procedures, check CMDh guidance and EOF practice before relying on a reclassified category.

How PQRA helps

PQRA supports marketing authorisation holders across the variations lifecycle: classifying changes under the new guidelines, building grouping and worksharing strategies, and drafting PACMPs that regulators can approve. Our regulatory and quality teams work together, so the dossier strategy reflects what your quality system can actually deliver.

Talk to PQRA about your post-approval change strategy →

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *